CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
0.5300
+0.0050 (0.95%)
At close: May 23, 2025, 4:00 PM
0.5251
-0.0049 (-0.92%)
After-hours: May 23, 2025, 7:54 PM EDT
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors.
The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Christopher Ehrlich |
Contact Details
Address: 201 Haskins Way, Suite 230 South San Francisco, California 94080 United States | |
| Phone | (650) 407-2376 |
| Website | cero.bio |
Stock Details
| Ticker Symbol | CERO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| ISIN Number | US71902K1051 |
| Employer ID | 87-1088814 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher B. Ehrlich M.B.A. | Chief Executive Officer and Chair |
| Andrew Albert Kucharchuk M.B.A. | Chief Financial Officer |
| Dr. Kristen Pierce Ph.D. | Chief Development Officer |
| Dr. Lawrence Corey M.D. | Co-founder and Head of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 8, 2025 | 8-K | Current Report |
| May 7, 2025 | ARS | Filing |
| May 7, 2025 | DEF 14A | Other definitive proxy statements |
| May 6, 2025 | D | Notice of Exempt Offering of Securities |
| May 2, 2025 | PRER14A | Filing |
| Apr 28, 2025 | 10-K/A | [Amend] Annual report |
| Apr 25, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 25, 2025 | 8-K | Current Report |